2
In recent years gain-of-function driver mutations in JAK2, MPL and CALR have been identified that constitutively activate JAK/STAT pathway signaling. 1, 2 Collectively, these mutations lead to the development of the vast majority of myeloproliferative neoplasms (MPNs), a group of related diseases including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (MF). Patients with MPNs have higher mortality rates, primarily due to cardiovascular complications, infections and transformation to other hematological malignancies such as leukaemias. 3 They also suffer significant constitutional symptoms including pruritus, headaches, weight loss, loss of appetite, fatigue and night sweats. Current MPN therapeutics include venesection to control blood counts in PV, aspirin to reduce the risk of thrombosis in both PV and ET and cytoreductive agents such as hydroxycarbamide to reduce blood counts. However, these treatments do not slow disease progression and provide little relief from sometimes debilitating constitutional symptoms. Recently, the JAK1/2 inhibitor ruxolitinib (rux) has emerged as a molecularly targeted therapy option. In trials, rux delivers significant survival benefits to MF patients, as well as a decrease in spleen size and constitutional symptoms. 4 Similarly, randomized trials in advanced PV patients also showed significant decreases in constitutional symptoms, spleen size and control of hematocrit in those receiving rux. 5 However, while effective, access to rux remains restricted and is not available to all patients that might benefit. Given these limitations, access to more affordable JAK/STAT pathway inhibitors would potentially address a significant unmet clinical need. Consistent with its role in disease, transgenic mice whose endogenous JAK2 locus has been replaced by the human JAK2 V617F allele develop ET-like disease when heterozygous and PV-like symptoms, including erythrocytosis and splenomegaly, when homozygous ( Fig S1, Ref 9 ). Both homozygotes and heterozygotes also have increased white cell counts ( Fig S1) . We therefore treated wild type and hJAK2 V617F age-matched littermates with either MTX or vehicle control (PBS) for 28 days using a low-dose regime previously shown to reduce rheumatoid arthritis-like symptoms in mouse models. 10, 11 Compared to controls, spleens of homozygous hJAK2 V617F mice contain increased levels of pSTAT5 and pSTAT3 ( Fig 1B) while mRNA levels of the JAK2/STAT5 target gene PIM1 is also increased (Fig 1C) . Strikingly, and consistent with in vitro results, homozygotes treated with MTX have reduced levels of pSTAT5 and pSTAT3 ( Fig 1B) and express significantly lower levels of the pathway target gene PIM1 (Fig 1C) suggesting that low-dose MTX also inhibits the JAK/STAT pathway in vivo.
We next tested hJAK2 V617F-expressing mice treated with MTX or rux as a positive control. 12 Increased hemoglobin levels in both heterozygous and homozygous hJAK2 V617F mice are significantly reduced following treatment with MTX (Fig 1D) , as are red blood cell counts and hematocrit levels ( Fig   S2A,B) . Importantly, despite being as effective than rux under these conditions, MTX treatment does not result in the general myelosuppression of wild type controls ( Fig 1D, Fig S2) and both controls and MTX treated mice continued to gain weight throughout the course of the experiment (not shown).
While platelet numbers and mean corpuscular volume are not significantly affected (Fig S2C,D) , MTX treatment is sufficient to normalize white cell counts (WCC) in both heterozygous and homozygous hJAK2 V617F mice, but does not affect the differentiation or relative levels of individual white blood cell subtypes (Fig S3) . Consistent with these findings, histological analysis of bone marrows (Fig 1E and S4) shows no reduction in cellularity or differentiation in any of the three hematopoietic lineages in MTX-treated animals. Homozygous animals do however have erythrocytic and megakaryocytic hyperplasia and polylobated nuclei in a proportion of megakaryocytes, as previously described 9 , phenotypes that are subjectively reduced in MTX-treated animals. As such, bone marrow morphology is consistent with a disease-specific effect of MTX, rather than non-specific myelosuppression.
Another MPN-related phenotype, and cause of considerable constitutional symptoms in patients, is splenomegaly. 13 By 10-11 weeks of age homozygous hJAK2 V617F mice have spleens around 3 times larger than wild type littermates, an enlargement that is strongly reduced by treatment with both MTX and rux (Fig 2A-B) . Histological analysis of these spleens shows that homozygotes have erythroid hyperplasia with red pulp expansion and loss of normal architecture, with occasional megakaryocyte clusters 9 , features which are mitigated by MTX treatment which show reduced erythroid infiltration and a correspondingly improved morphology of white pulp (Fig 2C and S5 ).
Although MTX treatment reduces spleen weight and reticulocyte numbers in JAK2 V617F homozygous mice ( Fig S6A-B) , we also observed modest increases in reticulocyte numbers and spleen size and in wild type littermates (Fig S6A,B) . Although the precise basis of these phenotypes is unclear, it is possible that splenic enlargement in wild type mice is associated with hypersplenism and increased red cell destruction. In this scenario, the elevated reticulocyte count is notable as it supports a model in which methotrexate is not causing myelosuppression, with the marrow being able to increase erythropoiesis and mount an appropriate reticulocyte response.
Intriguingly, we also observed slight increases in pSTAT5 and PIM1 mRNA levels in MTX-treated wild type animals ( Fig S6C,D) , changes that are not mirrored in JAK2 V617F homozygotes. While a detailed molecular analysis of the interactions between MTX and wild type JAK2 will be needed to elucidate the basis of these observations, it is possible that this observation may be relevant to the rare cases of MTX-induced lymphoma previously described in RA patients. 14 Finally, in order to gain insight into the potential mechanistic basis of MTXmediated effects we observed in vivo, we undertook an in silico study in which 6 a high resolution structure of the human JAK2 JH1 kinase domain 15 was used as a target onto which to dock MTX and ATP (Fig 2D-G 
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Methods
Mice
Groups of 6-7 week old male and female wildtype, heterozygote or homozygote JAKV617F mice were treated for 4 weeks with either vehicle (PBS), 5 mg/kg MTX (Sigma-Aldrich) given 3 times a week by intraperitoneal injection or 90 mg/kg Rux (SelleckChem, Houston,Texas,USA) given 5 times a week by oral gavage. All treatment protocols involving animals were approved by the UK Home Office (project licence PPL 70/8799/3-M).
Blood and histological analysis
Peripheral blood was taken by cardiac puncture from isoflurane sedated mice into EDTA coated tubes. Total and differential blood cell counts were measured by an automated Sysmex XN-10 FBC analyser. For histological analysis, tibiae and spleens were fixed in 10% formalin and processed for hematoxylin and eosin staining before imaging using a Zeiss Axioskop microscope and Q-imaging camera system.
Western Blots
Cells or mouse spleens were lysed in RIPA buffer containing proteinase and phosphatase inhibitors and processed for western blot analysis as previously shown 8 . Antibodies for pSTAT5, tSTAT5, pSTAT3, tSTAT3 (Cell signalling) and Actin (Abcam) were used.
Cell culture
Erythroleukaemia-derived JAK2 V617F-homozygous HEL cells were cultured and treated as described previously.
1 .
Real-time PCR
Quantitative real-time PCR was performed with a Biorad CFX96 as previously described 2 , using the ΔΔCt formula with actin as the housekeeping control gene.
Statistics and graphical representation
Graphs and the indicated statistical analyses were generated in Prism Version 5.01 (GraphPad software). Significance was determined using one-way Anova.
in silico modelling
We used protein structure 5TQ8 from the Protein Database 3 as the target for docking using Autodoc Vina software 4 implemented from the PyRx interface. 5 The protein structure was first prepared using pdbcur from the CCP4 suite. 6 Ligand structures were obtained from the RCSB website and processed with obabel v2.3.1 with correct protonation for pH 7. An exhaustiveness level of 16 was used for docking of all ligands. 
